Canon Medical Reinforces Commitment to AI Innovation With New Altivity Brand

Canon Medical has today announced the launch of Altivity, a new AI innovation brand, that consolidates machine learning and deep learning technologies to deliver uncompromised quality and value across the entire care pathway.

Canon Medical has been steadily redefining the role of AI in healthcare, starting with its Advanced intelligent Clear-IQ Engine (AiCE). Initially developed for CT, this denoising deep learning technology was soon deployed across MRI and PET/molecular imaging to help speed up scan times and improve image quality. Next came the launch of Automation Platform and AUTOStroke solution, both of which were designed to enhance clinical confidence and streamline workflows with the power of deep learning technology.

More recently, Canon Medical has transformed the ultrasound space with AI innovations*, that revolutionize clinical workflows. One of the most time-consuming aspects of an ultrasound exam is the care that must be taken to ensure serial measurements are done in a standardized and highly reproducible way. By leveraging the power of AI, Canon Medical has been able to automate these routine tasks to increase clinical productivity and reporting accuracy.

Under the promise of Intelligent healthcare made easy, Altivity enables:

  • Informed healthcare
    Altivity is here to help enhance clinical confidence with high-quality images and applications that help make informed decisions in real time.
  • Fast, tailored care
    Altivity has been created with patients in mind, to deliver the fast and accurate results they need for a more personalized treatment approach.
  • Efficient workflows
    Altivity helps create simple, streamlined AI-driven workflows that optimize resource deployment and ensure your teams have the insights they need to work smarter every day.

Toshio Takiguchi, President and CEO of Canon Medical, says of the launch, “We are passionate about the development of intelligent imaging solutions that reflect the changing medical landscape. With Altivity, we are strengthening our focus to help clinicians leverage their data and transform it into essential insight that improves outcomes for everyone.”

Naoki Sasaki, Head of Research and Development, echoed these sentiments by saying that “Canon Medical’s commitment to continued research and development has resulted in products that are establishing new standards in the area of AI in medicine and healthcare.”

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”